CN105412095A - Anti-diabetes oral drug composition - Google Patents
Anti-diabetes oral drug composition Download PDFInfo
- Publication number
- CN105412095A CN105412095A CN201510767088.4A CN201510767088A CN105412095A CN 105412095 A CN105412095 A CN 105412095A CN 201510767088 A CN201510767088 A CN 201510767088A CN 105412095 A CN105412095 A CN 105412095A
- Authority
- CN
- China
- Prior art keywords
- base
- methoxynaphthalene
- diabetes
- dimethyl
- chromane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
Abstract
The invention discloses an anti-diabetes oral drug composition. The anti-diabetes oral drug composition is prepared from 10-20 mg of 5-(3-hydroxy-7-methoxynaphthalene-2-base)-1, 1-dioxo-[1,2,5]thiadiazole-3-ketone sylvite, 20-30 mg of 3-(2-(2',6'-dimethyl-[1,1'-biphenyls]-3-base)-4,4-difluoro chroman-6-base) propionic acid, 200-300 mg of microcrystalline cellulose, 10-25 mg of crosslinking carboxymethyl cellulose sodium and 1-8 mg of magnesium stearate, and the using amount of active substances of the drug is reduced by at least 1/2 on the premise that the same treatment effect is achieved by compounding two different active substances.
Description
Technical field
The present invention relates to medical art, be specifically related to a kind of diabetes combination of oral medication.
Background technology
The metabolic disease of diabetes to be one group with hyperglycemia be feature.Hyperglycemia be then due to defect of insulin secretion or its biological agent impaired, or both have concurrently and cause.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.
The generally acknowledged form of usual existence two kinds of diabetes.In type 1 diabetes or insulin-dependent diabetes (IDDM), patient produces seldom or does not have insulin, regulates the hormone of glucose application.In type 2 diabetes mellitus or noninsulindependent diabetes (NIDDM), still produce insulin in the body.There is in the stimulation glucose of the patient suffering from type 2 diabetes mellitus in main insulin-sensitive tissue (it is muscle, liver and fatty tissue) and lipid metabolism the toleration to insulin action.These patients have the insulin of common level usually, and may have hyperinsulinemia (plasma insulin level of rising), because they compensate by the insulin of secretion rise the insulin effects reduced.Insulin resistance can not be caused by the Insulin receptor INSR reducing quantity but be caused by the rear Insulin receptor INSR binding deficient understood not yet completely substantially.This lacks and to cause in the oxidation of glucose in the activation of the insulin-mediated of inadequate picked-up, muscle and storage and fatty tissue glucose in lipidolysis and liver to produce to the responding ability of insulin and the suppression of insufficient insulin-mediated of secretion.
Current Remedies for diabetes is maintaining treatment effect, many employing 100mg active matter oral doses, and needs daily repeatedly to take.Due to the side effect of active matter, other health hazards are caused to patient, meanwhile, due to the increase of dosage, also make medicine cost increase, cause the raising for the treatment of cost.
Summary of the invention
The object of the invention is to propose a kind of diabetes combination of oral medication, its composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2.
For reaching this object, the present invention by the following technical solutions:
A kind of diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) 3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base)-4, the 4-bis-fluoro chromane-6-base) propanoic acid of 20-30mg
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
Described 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt and 3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base)-4,4-bis-fluoro chromane-6-bases) ratio of propanoic acid is less than 1.
Detailed description of the invention
The present invention is described pharmaceutical composition of the present invention by following embodiment.
Embodiment 1
I.5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
Step 1
3-benzyloxy-7-methoxynaphthalene-2-benzyl formate
5.0g (21.7mmol) 3-hydroxyl-7-methoxynaphthalene-2-formic acid, 9.29g (54.3mmol) benzyl bromide a-bromotoluene and the mixture of 9.01g (65.2mmol) potassium carbonate in 25mLDMF are stirred 24 hours in 60 DEG C.After being cooled to room temperature, by mixture impouring water, be extracted in EtOAc.Organic facies is washed with 3 × water and 1 × saturated NaCl.Use dried over sodium sulfate organic facies, under reduced pressure except desolventizing.Making residual solid crystallization from dichloromethane/ethanol, obtain title compound, is Tan solid, mp96-98 °.
H-NMR (CDCl): δ 8.25 (s, 1H), 7.61 (d, J=8.83Hz, 1H), 7.49 (d, J=7.35Hz, 2H), 7.46-7.30 (m, 7H), 7.24 (d, J=5.88Hz, 2H), 7.18 (dd, J=9.20 and 2.58Hz, 1H), 7.12 (m, 1H), 5.40 (s, 2H), 5.23 (s, 2H), 3.89 (s, 3H). analyze: CHO: value of calculation C, 78.38; H, 5.57. measured value C, 78.28; H, 5.56.
Step 2
3-benzyloxy-7-methoxynaphthalene-2-formic acid
In the suspension of 6.07g (20mmol) 3-benzyloxy-7-methoxynaphthalene-2-benzyl formate in 100mL ethanol, add 24mL1.0NNaOH (1.2 equivalent), mixture is stirred 4 hours in 60 DEG C, in stirring at room temperature 16 hours.Under reduced pressure except desolventizing, residual solid is dissolved in 50mL water.Use washed with diethylether solution, with 2NHCl acidify aqueous phase.Filtration gained precipitates, and washes with water, and dry, obtaining title compound, is faint yellow solid.
Mp177-179 ° of .H-NMR (CDCl): δ 11.01 (s, wide, 1H), 8.70 (s, 1H), 7.67 (d, J=8.82Hz, 1H), 7.53-7.41 (m, 5H), 7.37 (s, 1H), 7.27 (dd, J=8.83 and 2.57Hz, 1H), 7.20 (m, 1H), 5.36 (s, 2H), 3.92 (s, 3H). analyze: CHO: value of calculation C, 74.01; H, 5.23. measured value C, 73.71; H, 5.46.
Step 3
(3-benzyloxy-7-methoxynaphthalene-2-base)-t-butyl carbamate
In the suspension of the anhydrous t-BuOH+40mL dry toluene of 40mL, 2.3g (22mmol) triethylamine is added to 4.6g (14.9mmol) 3-benzyloxy-7-methoxynaphthalene-2-formic acid.In gained solution, add 5.34g (19.4mmol) DPPA, by mixture in stirring at room temperature 5 minutes, then stir 18 hours in 100 DEG C.Mixture is cooled to room temperature, then in impouring water.Mixture extraction is entered in EtOAc, wash organic facies with saturated NaCl.Under reduced pressure except desolventizing, residue uses hexane/ethyl acetate (85: 15) to carry out purification by flash chromatography, elutes title compound, is grease, slowly becomes waxy solid.
H-NMR(CDCl)：δ8.48(s，1H)，7.50(d，J＝8.82Hz，1H)，7.48-7.31(m，7H)，7.10(s，1H)，6.99(dd，J＝8.82and2.57Hz，1H)，5.17(s，2H)，3.84(s，3H)，1.54(s，9H).
Step 4
3-benzyloxy-7-methoxynaphthalene-2-base amine
By 4.99g (13.1mmol) (3-benzyloxy-7-methoxynaphthalene-2-base) solution of-t-butyl carbamate in 50mLTFA/ dichloromethane (1: 1) in stirring at room temperature 30 minutes.Under reduced pressure except desolventizing, 10% sodium bicarbonate aqueous solution is joined in residue.Mixture extraction is entered in EtOAc, use dried over sodium sulfate organic facies.Under reduced pressure except desolventizing, residue uses dichloromethane to carry out purification by flash chromatography, elutes title compound, makes its crystallization from ethanol, obtain white solid,
Mp149-151 ° of .H-NMR (CDCl): δ 7.54-7.32 (m, 6H), 7.09 (s, 1H), 6.92 (d, J=9.20Hz, 2H), 6.89 (dd, J=8.82 and 2.57Hz, 1H), 5.18 (s, 2H), 4.11 (s, wide, 2H), (3.87 s, 3H).
Step 5
(3-benzyloxy-7-methoxynaphthalene-2-base is amino)-methyl acetate
2.26g (14.8mmol) methyl bromoacetate is added in 2.76g (9.88mmol) 3-benzyloxy-7-methoxynaphthalene-2-base amine and the mixture of 2.73g (19.8mmol) potassium carbonate in 20mLDMF.Mixture is stirred 2 hours in 60 DEG C, then in stirring at room temperature 16 hours.By in mixture impouring water, be extracted in EtOAc.Wash organic facies with water (3 ×), saturated NaCl (1 ×), use dried over sodium sulfate.Under reduced pressure except desolventizing, making residue crystallization from ethanol, obtain title compound, is pale solid,
Mp129-131 °.; NMR (CDCl): δ 7.50 (s, wide, 2H), (7.49 d, J=8.46Hz, 1H), 7.45-7.33 (m, 3H), 7.07 (s, 1H), 6.97 (d, J=2.20Hz, 1H), 6.89 (dd, J=8.82 and 2.57Hz, 1H), 6.62 (s, 1H), 5.20 (s, 3H), 4.05 (s, 2H), 3.88 (s, 3H), 3.80 (s, 3H) .MS (M+1): 352. analyze: CHNO: value of calculation C, 71.78; H, 6.02; N, 3.99. measured value C, 71.61; H, 5.86; N, 3.91.
Step 6
N-(tertbutyloxycarbonyl sulfamoyl)-N-(3-benzyloxy-7-methoxyl group naphthyl) glycine methyl ester
The solution of 649mg (8.76mmol) tert-butyl alcohol in 3mL dichloromethane is dripped in the solution of 1.24g (8.77mmol) Carbimide. chlorine sulfonyl ester in 25mL dichloromethane.By solution in stirring at room temperature 30 minutes, then drip 2.2g (6.26mmol) (3-benzyloxy-7-methoxynaphthalene-2-base is amino)-methyl acetate and the solution of 1.27g (12.6mmol) triethylamine in 25mL dichloromethane.By mixture in stirring at room temperature 90 minutes, then wash with water.Use dried over sodium sulfate organic facies, under reduced pressure except desolventizing.Residual oil thing uses hexane/ethyl acetate (70: 30) to carry out purification by flash chromatography, elutes title compound, is grease.
H-NMR (CDCl): δ 8.10 (s, 1H), 7.68 (s, wide, 1H), 7.54 (d, J=9.80Hz, 1H), 7.49-7.29 (m, 5H), 7.17 (s, 1H), 7.14-7.08 (m, 2H), 5.23 (s, 2H), 4.63 (s, 2H), 3.86 (s, 3H), 3.68 (s, 3H), 1.41 (s, 9H) .MS (M-1): 529.
Step 7
N-sulfamoyl-N-(3-benzyloxy-7-methoxyl group naphthyl) glycine methyl ester
By 3.1g (5.85mmol) N-(tertbutyloxycarbonyl sulfamoyl)-N-(3-benzyloxy-7-methoxyl group naphthyl) solution of glycine methyl ester in 40mL trifluoroacetic acid/dichloromethane (1: 1) in stirring at room temperature 30 minutes.Under reduced pressure except desolventizing.Joined by dichloromethane in residue, then under reduced pressure (4x) removing, obtaining oily solid, it ground together with ether (16 hours), obtain title compound, is solid,
Mp137-139 °; H-NMR (CDCl): δ 8.01 (s, 1H), 7.58 (d, J=8.83Hz, 1H), 7.51-7.32 (m5H), 7.23-7.05 (m, 3H), 5.17 (s, wide, 2H), 5.15 (s, 2H), 4.39 (s, 2H), 3.85 (s, 3H), 3.67 (s, 3H) .MS (M+1): 431. analyze: CHNOS: value of calculation C, 58.59; H, 5.15; N, 6.51. measured value C, 58.53; H, 5.05; N, 6.62.
Step 8
5-(3-benzyloxy-7-methoxynaphthalene-2-base)-1; 1-dioxo-[1; 2,5] thiadiazolidine-3-ketone potassium salt drips the solution of 4.4mL1.0M potassium tert-butoxide in THF in 1.89g (4.39mmol) N-sulfamoyl-N-(3-benzyloxy-7-methoxyl group naphthyl) solution of glycine methyl ester in 5mLTHF.By mixture in stirring at room temperature 18 hours.Filter the dense thick precipitation of gained, wash with the THF of small size.Drying under reduced pressure solid, obtains title compound, mp182-198 °.
Step 9
5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
By 1.75g (4.01mmol) 5-(3-benzyloxy-7-methoxynaphthalene-2-base)-1, the 1-dioxo-solution of [1,2,5] thiadiazolidine-3-ketone potassium salt in 150mL water on 500mg10%Pd/C in 50psi hydrogenation 24 hours.Leach catalyst, with ethyl acetate washing containing filter liquor.By aqueous phase lyophilization, obtaining title compound, is light brown amorphous solid.
Mp260-265 ° of H-NMR (DMSO-d:7.90 (s, 1H), 7.54 (d, J=9.04Hz, 1H), 7.14 (s, 1H), 7.12 (d, J=2.64Hz, 1H), 6.98 (dd, J=9.04 and 2.64Hz, 1H), 4.20 (s, 2H), 3.81 (s, 3H) .MS (M-1): 307.
II.3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base)-4,4-bis-fluoro chromane-6-bases) propanoic acid
Steps A: 3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base)-4-oxo chromane-6-base) ethyl propionate.
Adopt 10%aq.HCl (0.1mL, 10.00 μm of ol) process 3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base) spiral shell [chromane-4,2'-[1,3] dioxolane]-6-base) solution of ethyl propionate (241mg, 0.509mmol) in acetone (5mL).Heat block is used this reactant mixture to be heated to 65 DEG C and to stir 1h.Then, this reactant mixture is cooled to room temperature, also concentrates under vacuo with NEt (1mL) neutralization.Gradient elution is adopted to use the thick residue of 0-30%EtOAc/ hexane purification gained by MPLC (ISCO24g).Merge the fraction needed, concentrated also dry to provide 3-(2-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-4-oxo chromane-6-base) ethyl propionate under vacuo.
1HNMR(500MHz，CDCl
3)δ7.76(d，1H)，7.47(m，2H)，7.37(dd，1H)，7.27(s，1H)，7.18(m，2H)，7.12(m，2H)，7.00(d，1H)，5.50(dd，1H)，4.13(q，2H)，3.08(dd，1H)，2.94(m，3H)，2.60(t，2H)，2.04(d，6H)，1.25(t，3H).
Step B:3-(2-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-4,4-difluoro chromane-6-bases) ethyl propionate
At room temperature adopt DAST (0.099mL, 0.749mmol) process 3-(2-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-4-oxo chromane-6-base) ethyl propionate (45mg, 0.105mmol), be placed in preheating 85 DEG C of heat blocks, then stir 6h.This reactant mixture is cooled to room temperature, dilutes with EtOAc (40mL) and pour in frozen water (5mL).Be separated organic layer, with DIHO (10mL), saturated NaHCO aqueous solution (10mL) washing, dry (NaSO), filters and concentrates under vacuo.Gradient elution is adopted to use the thick residue of 0-10%EtOAc/ hexane purification gained by (ISCO12g).Merge the fraction needed, concentrated also dry to provide 3-(2-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-4,4-difluoro chromane-6-bases) ethyl propionate under vacuo.
1HNMR(500MHz，CDCl
3)δ7.48(m，3H)，7.28(s，1H)，7.23(d，1H)，7.18(t，2H)，7.12(d，2H)，6.92(d，1H)，5.30(d，1H)，4.15(q，2H)，2.95(t，2H)，2.65(m，4H)，2.05(d，6H)，1.25(t，3H).
Step C:3-(2-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-4,4-difluoro chromane-6-bases) propanoic acid
Adopt 1M sodium hydrate aqueous solution (0.5mL, 0.500mmol) process 3-(2-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-4,4-difluoro chromane-6-base) solution of ethyl propionate (9mg, 0.020mmol) in THF (1mL)/MeOH (0.5mL).At room temperature stir this reactant mixture to spend the night.This reactant mixture concentrated, dilutes with aq.1MHCl (1mL) and uses EtOAc (20mL) to extract under vacuo.Be separated organic layer, dry (NaSO), filter, concentrated also dry to provide 3-(2-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-4,4-difluoro chromane-6-bases) propanoic acid under vacuo
1HNMR(500MHz，CDCl
3)δ7.50(m，3H)，7.28(dd，2H)，7.22(t，2H)，7.15(d，2H)，6.96(d，1H)，5，35(d，1H)，3.00(t，2H)，2.70(m，4H)，2.06(d，6H).
By the component I for preparing and II, obtain described diabetes combination of oral medication according to following dosage is composite:
(1) 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 15mg
(2) 3-(2-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-4, the 4-difluoro chromane-6-bases) propanoic acid of 30mg
(3) 268mg microcrystalline Cellulose,
(4) 20mg cross-linking sodium carboxymethyl cellulose, and
(5) 5mg magnesium stearate.
The bull C57BLob/ob mice in 11 week age is housed in reverse smooth circular chamber (from 6:00p.m. to 6:00a.m. illumination) with 6/cage, arbitrarily edible Purina Rodent Meal and drinking-water.At the 1st day, get tail blood sample at 8:00am, measure plasma glucose levels.Animal is randomized into matched group and compound group.The meansigma methods of the plasma glucose levels of each group is mated.Then the Orally administered solvent of animal (there is 0.5% carboxymethyl cellulose of 0.2% tween 80) or the compound (30mg/kg) in solvent is given.Every day, to mice administration, amounts to 3 days.At the 4th day, get basal blood specimens.Adopt the concentration of glucose of YSI2700 dual pathways biochemistry analyzer (YellowSpringsInstrumentCo., YellowSprings, OH) analysed for plasma sample, adopt ELISA algoscopy to measure insulin concentration.Test result shows, its concentration of glucose is 80-120mg/dL, its insulin concentration: 4.4 ~ 8.0mmol/L.
Comparative example 1
Containing the component I of 100mg, not containing component I I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 2
Containing the component I of 50mg, not containing component I I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Comparative example 3
Containing the component I I of 100mg, not containing component I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 4
Containing the component I I of 50mg, not containing component I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Above-described embodiment and comparative example explanation, diabetes combination of oral medication of the present invention, it is composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2, when two kinds of active matters that the present invention adopts are used alone, within the scope of equal volume, glucose in blood cannot be reduced in normal range of the present invention, prove to create cooperative effect between two kinds of active matters that the present invention adopts.
Applicant states, the present invention illustrates diabetes combination of oral medication of the present invention by above-described embodiment, but the present invention is not limited to above-mentioned specific components and formula, does not namely mean that the present invention must rely on above-mentioned detailed component and formula could be implemented.Person of ordinary skill in the field should understand, any improvement in the present invention, to equivalence replacement and the interpolation of auxiliary element, the concrete way choice etc. of each raw material of product of the present invention, all drops within protection scope of the present invention and open scope.
Claims (2)
1. a diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) 3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base)-4, the 4-bis-fluoro chromane-6-bases) propanoic acid of 20-30mg
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
2. diabetes combination of oral medication as claimed in claim 1, it is characterized in that, described 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt and 3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base)-4,4-difluoro chromane-6-bases) ratio of propanoic acid is less than 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510767088.4A CN105412095A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetes oral drug composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510767088.4A CN105412095A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetes oral drug composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105412095A true CN105412095A (en) | 2016-03-23 |
Family
ID=55490950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510767088.4A Pending CN105412095A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetes oral drug composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412095A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019059912A (en) * | 2017-06-28 | 2019-04-18 | フンダシオン セントロ デ インベスティガシオン コオペラティバ デ エネルヒアス アルテルナティバス セイセ エネルヒグネ フンダツィオアＦｕｎｄａｃｉｏｎ Ｃｅｎｔｒｏ Ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎ Ｃｏｏｐｅｒａｔｉｖａ Ｄｅ Ｅｎｅｒｇｉａｓ Ａｌｔｅｒｎａｔｉｖａｓ Ｃｉｃ Ｅｎｅｒｇｉｇｕｎｅ Ｆｕｎｄａｚｉｏａ | Solid polymer electrolyte based on modified cellulose, and application thereof in lithium or sodium secondary battery |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
-
2015
- 2015-11-11 CN CN201510767088.4A patent/CN105412095A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
Non-Patent Citations (2)
| Title |
|---|
| 杨玺: "《糖尿病合理用药》", 30 November 2007, 科学技术文献出版社 * |
| 陈培丰等: "《中西医结合临床内科学》", 31 August 2006, 浙江科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019059912A (en) * | 2017-06-28 | 2019-04-18 | フンダシオン セントロ デ インベスティガシオン コオペラティバ デ エネルヒアス アルテルナティバス セイセ エネルヒグネ フンダツィオアＦｕｎｄａｃｉｏｎ Ｃｅｎｔｒｏ Ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎ Ｃｏｏｐｅｒａｔｉｖａ Ｄｅ Ｅｎｅｒｇｉａｓ Ａｌｔｅｒｎａｔｉｖａｓ Ｃｉｃ Ｅｎｅｒｇｉｇｕｎｅ Ｆｕｎｄａｚｉｏａ | Solid polymer electrolyte based on modified cellulose, and application thereof in lithium or sodium secondary battery |
| JP7308580B2 (en) | 2017-06-28 | 2023-07-14 | フンダシオン セントロ デ インベスティガシオン コオペラティバ デ エネルヒアス アルテルナティバス セイセ エネルヒグネ フンダツィオア | Solid polymer electrolyte based on modified cellulose and its use in lithium or sodium secondary batteries |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160008385A1 (en) | Adrenomedullin production enhancer | |
| TW201043226A (en) | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof | |
| DE602004004156T2 (en) | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL ADMINISTRATION OF A GLUCAGON LIKE PEPTIDE (GLP) -1 COMPOUNDS OR A MEPANOLORTIN-4-RECEPTOR (MC4) AS AGONIST PEPTIDES | |
| CN105412095A (en) | Anti-diabetes oral drug composition | |
| CN105232552A (en) | Anti-diabetic oral drug composition | |
| CN105213379A (en) | A kind of diabetes combination of oral medication | |
| CN105213387A (en) | A kind of diabetes combination of oral medication | |
| CN105213381A (en) | A kind of diabetes combination of oral medication | |
| CN105520943A (en) | Anti-diabetics oral pharmaceutical composition | |
| CN105213384A (en) | A kind of diabetes combination of oral medication | |
| CN105434433A (en) | Antidiabetic oral drug composition | |
| CN105213385A (en) | A kind of diabetes combination of oral medication | |
| CN105287535A (en) | Anti-diabetes oral pharmaceutical composition | |
| CN105213383A (en) | A kind of diabetes combination of oral medication | |
| CN105287532A (en) | Anti-diabetic orally-administered pharmaceutical composition | |
| CN105213382A (en) | A kind of diabetes combination of oral medication | |
| CN105193796A (en) | Diabetes mellitus resistant oral medicine composition | |
| CN105434434A (en) | Antidiabetic oral drug composition | |
| RU2723486C2 (en) | Substituted aromatic compounds and pharmaceutical compositions for preventing and treating diabetes | |
| CN105193797A (en) | Diabetes mellitus resistant oral medicine composition | |
| CN105232546A (en) | Anti-diabetic oral drug composition | |
| CN105213386A (en) | A kind of diabetes combination of oral medication | |
| CN105287534A (en) | Anti-diabetes oral pharmaceutical composition | |
| CN105232545A (en) | Antidiabetic oral drug composition | |
| CN103626722B (en) | Nitric oxide donator type Hypoglycemics, Preparation Method And The Use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160323 |
|
| WD01 | Invention patent application deemed withdrawn after publication |